CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer's Dementia Spectrum.

Maryam Behzad Negin Zirak Ghazal Hamidi MadaniLinda BaidooAli RezaeiShima KarbasiMohammad SadeghiMahnaz Shafiei Mahsa Mayelinull Alzheimer's Disease Neuroimaging Initiative

Published in: International journal of Alzheimer's disease (2023)

Our research suggests potential early diagnostic and prognostic utilities for certain peptides extracted from CSF-targeted proteomics research. The ethical approval of ADNI is available at ClinicalTrials.gov with Identifier: NCT00106899.

Keyphrases

mass spectrometry
cancer therapy
mild cognitive impairment
label free
cognitive decline
cerebrospinal fluid
drug delivery
decision making
amino acid
risk assessment
climate change